Antiplatelet agent vs control
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review
- RR 0.52 [0.38, 0.7]8 studies · 1525 participantsLow